左乙拉西坦预防小儿偏头痛——一项开放标签研究。
Levetiracetam prophylaxis in pediatric migraine--an open-label study.
作者信息
Pakalnis Ann, Kring Donna, Meier Lisa
机构信息
Department of Neurology, Children's Hospital, Columbus, OH 43205, USA.
出版信息
Headache. 2007 Mar;47(3):427-30. doi: 10.1111/j.1526-4610.2007.00728.x.
BACKGROUND
Migraine is common in the pediatric population. Levetiracetam, an anti-epileptic drug, has shown some efficacy in small prospective adult headache studies.
METHODS
We prospectively evaluated levetiracetam in an open-label study in 20 pediatric migraine patients to assess tolerability and efficacy.
RESULTS
Eighteen of 20 patients had significant reduction in headache frequency. PedMIDAS showed significant decrease in disability scores, side effects were minimal (mild behavioral changes).
CONCLUSION
Levetiracetam had some efficacy in reducing migraine frequency and disability. Further larger studies are warranted, possibly utilizing a placebo-controlled design.
背景
偏头痛在儿科人群中很常见。左乙拉西坦是一种抗癫痫药物，在小型前瞻性成人头痛研究中已显示出一定疗效。
方法
我们在一项开放标签研究中对20名儿科偏头痛患者进行了前瞻性评估，以评估左乙拉西坦的耐受性和疗效。
结果
20名患者中有18名头痛频率显著降低。儿童偏头痛残疾评估量表（PedMIDAS）显示残疾评分显著下降，副作用最小（轻微行为改变）。
结论
左乙拉西坦在降低偏头痛频率和残疾方面有一定疗效。有必要进行进一步的更大规模研究，可能采用安慰剂对照设计。
Zotero 插件